Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 14 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 11 12 13 14 presentations: 1 to 25 of 341
Computational Cancer Epigenomics
Genome-scale analysis of DNA methylation in cancer: Discoveries, challenges, and opportunities
Hui Shen
Van Andel Research Inst., Grand Rapids, MI, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Computational Cancer Epigenomics
Prioritizing non-coding variants in cancer genomes using epigenetic profiles
Peter J. Park
Harvard Medical School, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Computational Cancer Epigenomics
Modeling cancer gene regulation with public ChIP-seq profiles
X Shirley Liu
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Chairperson
Elizabeth M. Jaffee
Johns Hopkins University, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Successes and challenges in designing combination immunotherapy clinical trials for breast cancer
Leisha A Emens
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Issues faced by industry in developing safe and effective combination immunotherapies
Ira Mellman
Genentech, Inc., South San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
Statistical challenges in designing combination immunotherapy clinical trials
Katy Simonsen
Bristol-Myers Squibb Co., Princeton, NJ, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Clinical Trials Design Methods Workshop, Part 2: Breakthroughs and Challenges of Combination Immunotherapy Trials
FDA's point of view on trial designs for accelerating combination immunotherapies across multiple tumor types
Tatiana Prowell
U.S. Food and Drug Administration, Silver Spring, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Emerging Targets for the Treatment of Lung Cancer
Resistance to targeted therapies in lung adenocarcinoma
Mark Awad
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Emerging Targets for the Treatment of Lung Cancer
Emerging targets in lung adenocarcinoma
Eric A. Collisson
UCSF, San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Emerging Targets for the Treatment of Lung Cancer
Treatment advances in squamous cell lung cancer and immunotherapy in NSCLC
Esra A Akbay
DFCI, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Emerging Targets for the Treatment of Lung Cancer
Treatment advances in small cell lung cancer
Daniel Morgensztern
Washington Univ., Saint Louis, MO, United States
from AACR Annual Meeting 2016 on April 16, 2016 10:15 AM-12:15 PM
Alterations and Inhibition of the Spliceosome
Basic mechanisms of splicing catalysis and regulation
Clara L Kielkopf
University of Rochester Medical Center, Rochester, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
Genetics and biological studies of spliceosomal mutations in cancer
Matthew Walter
Washington University, Saint Louis, MO, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
Understanding and targeting SF3B1 in cancer
Silvia Buonamici
H3 Biomedicine, Boston, MA, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Alterations and Inhibition of the Spliceosome
The role of splicing regulatory proteins in cancer
Omar I Abdel-Wahab
Mem. Sloan-Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2016 on April 16, 2016 1:00 PM-3:00 PM
Tumor Heterogeneity
Deciphering cancer genome evolution and intra-tumor heterogeneity: The TRACERx Analysis Pipeline
Gareth A Wilson
The Francis Crick Institute, London, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Detecting mutational signatures in heterogeneous tumors
Ludmil B Alexandrov
Los Alamos National Laboratory, Los Alamos, NM, United States
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Neutral evolution in cancer: Making sense of intra-tumor heterogeneity
Andrea Sottoriva
The Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Tumor Heterogeneity
Inferring the clonaldynamics underlying histologically transformed and treatment resistant follicular lymphomas
Fong Chun Chan
BC Cancer Agency Vancouver BC, Vancouver, BC, Canada
from AACR Annual Meeting 2016 on April 16, 2016 3:15 PM-5:15 PM
Inflammation and Cancer: Targeting the Myeloid Microenvironment
Macrophage PI3Kgamma drives cancer immune suppression
Judith A. Varner
UCSD Moores Cancer Center, La Jolla, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
Inflammation and Cancer: Targeting the Myeloid Microenvironment
Deciphering mechanisms of resistance to macrophage-targeted therapies
Johanna A. Joyce
Ludwig Institute for Cancer Research, Lusanne, Switzerland
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
Inflammation and Cancer: Targeting the Myeloid Microenvironment
Paracrine nexus of intratumoral leukocytes: Fueling response and resistance of immunotherapies
Lisa M. Coussens
OHSU Knight Cancer Institute, Portland, OR, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:00 PM
New Drugs on the Horizon 1
Co-Chairperson
Indrawan J. Mcalpine
Pfizer Global R&D, San Diego, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
New Drugs on the Horizon 1
Discovery and pre-clinical pharmacology of AZD0156: A first-in-class potent and selective inhibitor of Ataxia telangiectasia mutated (ATM) kinase
Elaine Cadogan
AstraZeneca, Cambridge, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
<< first | < prev page: of 14 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 11 12 13 14 presentations: 1 to 25 of 341